203 related articles for article (PubMed ID: 35776908)
1. Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL.
Rejeski K; Wu Z; Blumenberg V; Kunz WG; Müller S; Kajigaya S; Gao S; Bücklein VL; Frölich L; Schmidt C; von Bergwelt-Baildon M; Feng X; Young NS; Subklewe M
Blood; 2022 Nov; 140(20):2175-2179. PubMed ID: 35776908
[TBL] [Abstract][Full Text] [Related]
2. Safer CAR T-Cell Therapy.
Abbasi J
JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
[No Abstract] [Full Text] [Related]
3. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
4. CAR T cells - what have we learnt?
Nat Rev Clin Oncol; 2017 Dec; 15(1):1. PubMed ID: 29242589
[No Abstract] [Full Text] [Related]
5. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
6. Beyond CD19 CAR-T cells in lymphoma.
Leung WK; Ayanambakkam A; Heslop HE; Hill LC
Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy for early loss of B-cell aplasia after anti-CD19 CAR T-cell therapy.
Gabelli M; Oporto-Espuelas M; Burridge S; Chu J; Farish S; Hedges E; Ware K; Williams L; Young L; Alajangi R; Ancliff P; Bartram J; Bonney D; Chenchara L; Chiesa R; Cugno C; Hodby K; Jalowiec KA; Lazareva A; Lucchini G; Mirci-Danicar OC; Mullanfiroze K; Pavasovic V; Rao A; Rao K; Riley L; Samarasinghe S; Shenton G; Silva J; Vora A; Hough R; Amrolia PJ; Ghorashian S
Blood Adv; 2024 Apr; 8(8):1959-1963. PubMed ID: 37820111
[No Abstract] [Full Text] [Related]
10.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy: Full speed ahead.
Sermer D; Brentjens R
Hematol Oncol; 2019 Jun; 37 Suppl 1():95-100. PubMed ID: 31187533
[TBL] [Abstract][Full Text] [Related]
13. The use of chimeric antigen T-cell therapy in chronic lymphocytic leukemia.
Siddiqi T
Clin Adv Hematol Oncol; 2022 Jun; 20(6):366-368. PubMed ID: 35731607
[No Abstract] [Full Text] [Related]
14. Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.
Mikhailova E; Illarionova O; Shelikhova L; Zerkalenkova E; Molostova O; Olshanskaya Y; Novichkova G; Maschan A; Maschan M; Popov A
Haematologica; 2022 Apr; 107(4):970-974. PubMed ID: 34911282
[No Abstract] [Full Text] [Related]
15. Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies.
Zurko JC; Xu H; Chaney K; Schneider D; Szabo A; Hari P; Johnson BD; Shah NN
Cytotherapy; 2022 Aug; 24(8):767-773. PubMed ID: 35597752
[TBL] [Abstract][Full Text] [Related]
16. CD19-Targeting CAR T-Cell Therapy for Antisynthetase Syndrome.
Lundberg IE; Galindo-Feria AS; Horuluoglu B
JAMA; 2023 Jun; 329(24):2130-2131. PubMed ID: 37367988
[No Abstract] [Full Text] [Related]
17. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.
Orlando EJ; Han X; Tribouley C; Wood PA; Leary RJ; Riester M; Levine JE; Qayed M; Grupp SA; Boyer M; De Moerloose B; Nemecek ER; Bittencourt H; Hiramatsu H; Buechner J; Davies SM; Verneris MR; Nguyen K; Brogdon JL; Bitter H; Morrissey M; Pierog P; Pantano S; Engelman JA; Winckler W
Nat Med; 2018 Oct; 24(10):1504-1506. PubMed ID: 30275569
[TBL] [Abstract][Full Text] [Related]
18. CAR T-Cells for Cure in Pediatric B-ALL.
Gardner RA; Shah NN
J Clin Oncol; 2023 Mar; 41(9):1646-1648. PubMed ID: 36634289
[No Abstract] [Full Text] [Related]
19. A New Frontier: CD19 Chimeric Antigen Receptor T-Cell Therapy.
Alcocer Alkureishi L; Hageman JR
Pediatr Ann; 2024 May; 53(5):e157-e158. PubMed ID: 38700917
[No Abstract] [Full Text] [Related]
20. FDA Investigating CAR-Related T-cell Malignancies.
Cancer Discov; 2024 Jan; 14(1):9-10. PubMed ID: 38032843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
